

CHANGING THE LEVELS OF PRO-AND ANTI-INFLAMMATORY CYTOKINES IN PATIENTS WITH GENERALIZED PERIODONTITIS IN CONJUNCTION WITH THE METABOLIC SYNDROME UNDER THE INFLUENCE OF COMBINED TREATMENT WITH DRUGS THAT INCREASE INSULIN SENSITIVITY

D. U. Kruchkov

SUMMARY

The article presents the data of its own research, whose goal was to study the dynamics of the levels of pro-and anti-inflammatory cytokines in the saliva of patients with generalized periodontitis in conjunction with the metabolic syndrome on a background of complex treatment with drugs that increase insulin sensitivity.

: , , , .
 () -6 (-6) - [2, 9].
 , - , -4 -
 , - , -
 [2, 3, 6]. - [3,7, 12].
 , - , -
 -1 (-1) - (-) [1, 6, 7]. (), -
 -4 (-4) [4, 11, 13]. [5, 8].
 , - , -

, -6, - , . -
 [10, 14, 15]. 6 « » 1 .3
 , - , -
 , - , -
 - (« ») 500 6
 , -
 :
 - , « ».
 30 ,
 12 .
 , I-II 96
 Microsoft Excel Statistica V.6.
 , 2005 .(2009 .). <0,05.
 : III , (-1 , -6, -)
 33 - -4
 , -
 32 .
 : , 40-55 . -1
 () -1
 (188,11 ± 28,52 /)
 « - - - », « -4- (190,71 ± 26,52 /) 1,6
 - », « -6- - » « (117,01
 -1 - - »(« - », . ± 4,38 /),
 , -1
 -1
 LabLine-022
 ().
 , 3 : , 6
 , -6
 (). (287,88 ± 24,15 /) 1,3
 -6
 5% (216,51 ± 20,71 / , <0,05).
 14, , -6
 (255,22 ± 22,42 /) - 1,1 ,
 , (216,51 ± 20,71 / , <0,05).

-1 , -6, -4, , (±m)

-1 (/)	188,11 ± 28,52*	190,71 ± 26,52*	117,01 ± 4,38
-6 (/)	287,88 ± 24,15* **	255,22 ± 22,42*	216,51 ± 20,71
-4 (/)	5,76 ± 1,13*	6,23 ± 1,28*	11,39 ± 1,58
- (/)	201,56 ± 9,96* **	159,25 ± 9,86*	69,65 ± 6,46

1) * - <0,05 ; 2)** - <0,05 ;

3) n -

-6 - -4 -

(287,88 ± 24,15 (5,76 ± 1,13 /), 1,9 ,

(255,22 ± 22,42 / , <0,05) (11,39 ± 1,58 / , <0,05).

-6 -4 -

(6,23 ± 1,28 /) 1,8 ,

(11,39 ± 1,58 / , <0,05).

-4

(201,56 ± 9,96 /) 2,8 -

(69,65 ± 6,46 ,

/).

(201,56 ± 9,96 /), -

-(159,25 ± 9,86 / , <0,05) -4. -1 , -6, -

1,2 . -

-4 , 2.

2

, (±m)

	(n=33)		(n=32)		(n=31)	
-1 (/)	195,7 ± 24,53	146,78** ± 20,02	183,38 ± 31,08	150,05** ± 25,25	184,40 ± 28,98	157,07** ± 25,64
-6 (/)	290,29 ± 19,28	225,92** ± 25,46	289,8 ± 23,82	249,33** ± 26,41	281,1 ± 30,99	263,98* ± 30,13
- (/)	203,63 ± 9,34	152,79** ± 11,29	199,79 ± 10,75	173,13** ± 12,35	201 ± 9,58	183,52** ± 10,93
-4 (/)	5,56 ± 1,19	9,2** ± 1,1	5,75 ± 1,03	8,65** ± 0,97	6,01 ± 1,12	7,57** ± 1,29

1) *

(<0,05).

2) **

(<0,001).

4. 10. -
 2 / . . . // - - - / -2009.-
 .-2007.- 3.- .24-29. . . // -2009.-
 5. - 3 (5).- .39-42.
 , - 11. / . . . //
 , - -2004.- 1.- .73-75.
 , - 12. -
 , - - /
 .- .,2009.-40 . - 2005.- 3 (31).- .71-73.
 6. . . . / . . . - 13.
 .- : - ,2007.-504 . NO
 7. /

 .: ,2008.-614 . / . . //
 8. . . . « - : III
 » / ,2008.- .2.
 . // . -
 2012.- 2 (88).- 157-160. 14. Higher production of IL-6 in visceral vs. subcutaneous
 9. adipose tissue. Implication of nonadipose cells in adipose
 tissue/ ruun J.M., Lihn A.S., Madan A.K. et al. // Amer. J.
 - Physiol. Endocrin. Metab.- 2004.- Vol. 286.- P. E8-E13.
 / . . . - 15. Day K. Metabolic syndrome, or what you will:
 - definitions and epidemiology/ Day K. // Diab. Vasc.
 . . . // Dis. Res.- 2007.- Vol. 4, 1.- .32-38
 .-2008.- 5.- .56.